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Abstract
Adrenocortical carcinoma (ACC) is a rare, but highly malignant tumor of unknown origin. Inhibin a-subunit (Inha) knockout
mice develop ACCs following gonadectomy. In man, INHA expression varies widely within ACC tissues and its circulating
peptide inhibin pro-aC has been described as a novel tumor marker for ACC. We investigated whether genetic and
epigenetic changes of the INHA gene in human ACC cause loss or variation of INHA expression. To this end, analyses of INHA
sequence, promoter methylation and mRNA expression were performed in human adrenocortical tissues. Serum inhibin
pro-aC levels were also measured in ACC patients. INHA genetic analysis in 37 unique ACCs revealed 10 novel, heterozygous
rare variants. Of the 3 coding bases affected, one variant was synonymous and two were missense variants: S72F and S184F.
The minor allele of rs11893842 at 2124 bp was observed at a low frequency (24%) in ACC samples and was associated with
decreased INHA mRNA levels: 4.761.9 arbitrary units for AA, compared to 26611 for AG/GG genotypes (P = 0.034). The
methylation of four proximal INHA promoter CpGs was aberrantly increased in five ACCs (47.763.9%), compared to normal
adrenals (18.460.6%, P = 0.0052), whereas the other 14 ACCs studied showed diminished promoter methylation (9.861.1%,
P = 0.020). CpG methylation was inversely correlated to INHA mRNA levels in ACCs (r =20.701, p = 0.0036), but not
associated with serum inhibin pro-aC levels. In conclusion, aberrant methylation and common genetic variation in the INHA
promoter occur in human ACCs and are associated with decreased INHA expression.
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Introduction
Adrenocortical carcinoma (ACC) is a rare malignancy with a
poor survival rate [1,2]. The occurrence of ACC has a female
preponderance and a bimodal distribution with an increased
incidence in children and in adults over 60 years [3]. Familial
ACC occurs in the context of genetic syndromes, such as
Beckwith-Wiedemann syndrome [4] and Li-Fraumeni syndrome
[5]. Mutations in genes underlying these disorders have also been
linked to sporadic ACC formation, especially in the case of TP53
[6]. The most frequent alteration found in ACC is overexpression
of the maternally imprinted IGF-II locus [7]. More recently,
mutations in the Wnt/b-catenin pathway have been shown to
occur during adrenocortical tumor progression [8]. Genetic causes
and the role of chromosomal aberrations in adrenocortical
tumorigenesis remain largely unknown.
The inhibin a-subunit (encoded by INHA) forms inhibin A or B
by coupling to the inhibin bA- or bB-subunits, respectively. Its
expression is limited to the gonads, placenta and adrenal cortex.
The principal effect of circulating inhibins A and B is inhibition of
local activin-induced follicle-stimulating hormone (FSH) secretion
in the pituitary gland [9]. In a murine knockout model, the inhibin
a-subunit was found to have a tumor suppressive role for gonadal
tissue [10] and, after gonadectomy, for the adrenal cortex [11].
Ninety-nine percent of Inha 2/2 mice developed adrenocortical
steroid-secreting carcinomas after gonadectomy [11]. Pathways
involved in this effect include the differentiation into granulosa
cell-like cells with expression of fetal or gonadal markers such as
Gata4, Lhr, Fshr and Cyp17a1 [12]. Inha-related carcinogenesis
in mice has also been attributed to decreased activin signalling
potential and aberrant expression and effects of TGF-b2 [13,14].
In man, the function of adrenal inhibins is unknown, although
its counterpart activin A has been described to be involved in the
zone-specific regulation of adrenocortical steroidogenesis [15].
The evidence for INHA as a tumor suppressor in human ACC is
conflicting. Several mRNA and protein analysis studies have
shown lack of INHA expression in a proportion of patients with
ACC as well as INHA overexpression in another subset
[16,17,18,19,20]. Recently, we reported that serum levels of the
free peptide form of the a-subunit, inhibin pro-aC, were increased
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in patients with adrenocortical carcinomas and that these levels
can be utilized as a tumor marker [21]; inhibin pro-aC levels may
be useful for the differentiation between malignant and benign
adrenocortical tumors as well as for follow-up of individual
patients. Although the majority of ACC patients showed increased
serum levels of inhibin pro-aC a subset of patients had normal
levels, possibly representing the tumors that do not express INHA
[21].
Several DNA alterations are known to influence gene expression
during tumorigenesis. Apart from the genetic changes causing
aberrant or absent expression, epigenetic alterations, such as
chromatin remodelling and CpG methylation, can affect gene
transcription and frequently occur in cancer [22]. Methylation of
CpG islands in gene promoter regions can result in transcriptional
silencing and loss of gene expression due to interference with the
binding of transcription factors [23].
Insights into the regulatory control of INHA expression could
shed further light on the role of INHA in human adrenal
tumorigenesis and on the variability of serum free circulating
inhibin levels that could function as serum tumor marker in ACC
patients. In order to unravel this we investigated the regulatory
mechanisms of INHA expression in human ACC. Sequencing of
the INHA gene was undertaken to search for genetic variants that
could affect gene function or expression levels. Furthermore,
quantitative methylation analysis of the INHA promoter was
performed in order to study whether methylation of CpGs
contributes to the differences in expression. These analyses were
coupled to tumor mRNA levels of the inhibin a-subunit and serum
concentrations of inhibin pro-aC.
Materials and Methods
Sample collection
Paraffin-embedded tissue blocks were collected from the
pathological archives of the Erasmus MC. Tissue samples
originated from patients operated between 1991 and 2010 in this
hospital. The diagnosis of adrenocortical carcinoma was made if
the van Slooten index exceeded 8 [24]. Tumor staging was
performed according to the European Network for the Study of
Adrenal Tumors (ENSAT) staging system [1]. Haematoxylin and
eosin-stained slides were evaluated by a pathologist and sections
with a high percentage of viable tumor cells were microdissected
for further analysis. Tissues excised before 2007 were collected
from the pathological archives of the Erasmus MC. Informed
consent for the secondary use of surplus tissue was obtained from
all patients verbally prior to surgery. Patient refusal to make tissue
available for research was recorded in writing and these samples
were not included in this study accordingly. From 2007 and
onwards, samples were collected in a prospective study of adrenal
tumors and informed written consent was obtained from all
participants. These samples also included adrenal tissues from
patients who underwent adrenalectomy due to renal cell
carcinoma, adrenal hyperplasia and adenoma. Tumor sections
were collected from viable tumor parts and snap-frozen in liquid
nitrogen or dry ice shortly after resection. Pre-operative serum
levels of inhibin pro-aC were measured in patient subsets using an
enzyme-linked immunometric assay (Diagnostic Systems Labora-
tory, Webster, TX, USA). The study was performed according to
the Dutch regulations on the use of residual tissues and approved
by the Medical Ethics Committee of the Erasmus MC.
DNA sequencing
DNA was isolated with a DNA mini kit (Qiagen, Venlo, The
Netherlands) according to manufacturer’s protocol and dissolved
in H2O. Its concentration was measured using a Nanodrop
dispenser (Thermo Fisher Scientific, Waltham, MA, USA).
The inhibin a-subunit gene, located at 2q35, is composed out of
two exons (Figure 1). For DNA analysis of paraffin-embedded
tissues primer pairs were selected to amplify regions of 200–
250 bp. For freshly frozen tissues regions up to 500 bp could be
successfully amplified. Primer locations are summarized in
Table 1. The primers covered the coding region, up to 2
331 bps from the ATG start site (containing the cAMP binding,
SF-1 response and GATA elements at 2151 to 2112 bps [25,26])
and at least 153 bps of intron adjacent to exon-intron boundaries
(Figure 1).
PCR amplication was performed in a 30 ml volume of 0.05 U/
ml FastTaq polymerase (Roche Applied Science, Almere, The
Netherlands), 1 ng/ml DNA, 250 nM forward and reverse
primers, 200 mM dNTPs (Amersham Biosciences, Uppsala,
Sweden) and buffer containing MgCl2 (Roche) in a GeneAmp
9700 (Applied Biosystems, Nieuwerkerk aan den IJssel, The
Netherlands) under the following conditions: 7 minutes at 95uC,
followed by 40 cycles of 1 minute intervals at 95uC, 56–63uC and
72uC, ending with 10 minutes at 72uC. PCR products were
purified by High Pure PCR Product Purification Kit (Roche).
Both forward and reverse PCR primers were used in separate
sequence reactions with the BigDye Terminator v1.1 Cycle
Sequencing Kit (Applied Biosystems). Three ml of purified PCR
product was used with 500 nM of primer in a reaction of 1 minute
at 96uC and 25 cycles of 30 seconds at 96uC, 15 seconds at 50uC,
and 4 minutes at 60uC. The sequence reaction products were
purified with the use of the Dye-Ex 96 Purification Kit (Qiagen)
and Micro-Bio-Spin Purification Columns (Bio-Rad, Veenendaal,
The Netherlands). Sequence detection was performed using the
ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
Sequencher software (Genes Codes Corporation, Ann Arbor,
MI, USA) was used for DNA analysis.
Methylation analysis
One mg of DNA, obtained from frozen samples, was treated
with bisulfite using the EZ DNA methylation kit (Zymo research,
Irvine, CA, USA), eluted in 100 ml H2O and stored at 280uC.
Bisulfite-treated DNA in the promoter region of INHA was
amplified by PCR while a T7 promoter was introduced in the
reverse primer. Using EpiDESIGNER software provided by
Sequenom (San Diego, CA, USA) two primer sets were designed
that covered multiple CpG dinucleotides upstream of the INHA
start site (Figure 1); the primer sequences are described in Table 1.
The PCR was performed in a 5 ml volume containing 0.04 U/
ml HotStar Taq polymerase (Qiagen), 200 mM dNTPs, 200 nM of
both primers, 1 ml of bisulfite-treated DNA, HotStar PCR buffer
and H2O. After 10 minutes at 95uC, 35 cycles were performed of
30 seconds at 95uC, 30 seconds at 53uC and 45 seconds at 72uC.
The reaction ended with a 7 minute annealing step at 72uC. After
Figure 1. The human inhibin a-subunit (INHA) gene. Located at
2q35, INHA is composed of two exons separated by a 2 kb intron. The
coding sequence is composed of 1101 bps. The regions sequenced in
this study are indicated by the continuous arrows. The areas
investigated for methylation are depicted by the dashed arrows; CpG
dinucleotides successfully characterized are shown as open circles.
doi:10.1371/journal.pone.0104944.g001
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confirmation of PCR product on a 2% agarose-containing gel, the
product was treated with 0.3 U Shrimp Alkaline Phosphatase for
20 minutes at 37uC and 5 minutes at 85uC.
Next, in vitro transcription and base-specific cleavage was
performed in a 7 ml mixture containing 20 U T7 R&DNA
polymerase, T-specific cleavage mix, 3.14 mmol/l DTT, RNase
A, PCR product and T7 polymerase buffer (Sequenom). The
resulting fragments were diluted with H2O and 6 mg of CLEAN
resin was added for 10 minutes to remove sodium and potassium
ions. This mixture was centrifuged at 3000 rpm for 5 minutes and
dispensed on a SpectroCHIP with the MassARRAY Nanodis-
penser RS-1000 instrument (Sequenom). Quantitative methylation
was detected by a matrix assisted laser desorption/ionisation time-
of-flight (MALDI-TOF) mass spectrometer (MassARRAY Ana-
lyzer Compact, Sequenom) and analysis was performed using
accompanying EpiTYPER software.
Standard curves for these assays were constructed by assaying
mixtures of mixed DNA samples containing 0% to 100%
methylation with intervals of 10%. Methylation analysis was
successful for 8 CpGs in the INHA promoter: located 149, 203,
Table 1. Primer sequences (59 to 39).
sequence Forward position
INHA TGTGTGTAGGGAGAAGGTGTT 2331
INHA GGAAGACTGGATGAGAAGGG 2134
INHA TTCTTGCTGCTGACCCC 22
INHA CTGGTGGCCACATCCCTG IVS1-89
INHA AGAGTGCAGCCCATCATT IVS1-116
INHA CCATCCATGTAGACACCATTC IVS1-386
INHA GCACAGCAGCCTCCAATA 422
INHA TCCCCTCTGTACCTGCTCA 600
INHA ATGCCAACTGCCACAGAGTA 776
INHA CGGATGGAGGTTACTCTTTCA 1031
Reverse
INHA CACCCACCCTCTTCTACC 299
INHA GCCAGAACAAGTTCCCG 92
INHA TGCTTTTTCTCAAAGTCATCC IVS1+45
INHA GGGAGACAGAAGCATAAGGA IVS1+153
INHA GGGGCTCAGAGCTATTGG 451
INHA CGGTGACAGTGCCAGCAG 477
INHA GACATCAGGGGAGTTGAGC 713
INHA AAACTGGGAGGGTACACGAT 857
INHA GAGAAGGTTGGGCACTGTCT 1077
INHA AGATCTGACAGTCCCATGCTC 69 bp 39 of INHA
methylation Forward
INHA AGGAAGAGAGGTTGTTTGGTTTTTTGTTTTTAGGA 2842
INHA AGGAAGAGAGTTGATGTTATTTTTGGATGTGTTTG 2437
Reverse
INHA CAGTAATACGACTCACTATAGGGAGAAGGCT AACCTTCTAAAACCCCTTTCAATAA 2532
INHA CAGTAATACGACTCACTATAGGGAGAAGGCT TAATAAAAAACTCACACCCTACCCC 226
mRNA Forward
INHA CCGAGGAAGAGGAGGATGTCT 221
HPRT1 TGCTTTCCTTGGTCAGGCAGTAT 293
GAPDH ATGGGGAAGGTGAAGGTCG 1
Reverse
INHA CGGTGACAGTGCCAGCAG 477
HPRT1 TCAAATCCAACAAAGTCTGGCTTATATC 545
GAPDH TAAAAGCAGCCCTGGTGACC 70
probe (FAM-TAMRA labeled)
INHA TGACTTCAGCCCAGCTGTGGTTCCA 377
HPRT1 CAAGCTTGCGACCTTGACCATCTTTGGA 489
GAPDH CGCCCAATACGACCAAATCCGTTGAC 47
doi:10.1371/journal.pone.0104944.t001
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241, 285, 558, 599, 719 and 751 bps upstream of the INHA start
site.
mRNA analysis
Total RNA was isolated from frozen adrenocortical tissues by
Trizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse
transcriptase and quantitative polymerase chain reaction of INHA
and housekeeping genes HPRT1 and GAPDH were performed in
duplicate as previously described [16]. Sequences of primers and
probes have been indicated in Table 1. Expression levels of INHA
were calculated relative to that of the average threshold cycle (Ct)
of GAPDH andHPRT1 using the delta-Ct method and multiplied
by 1000.
Statistical analysis
The dataset for this study is included in Table S1. Analyses of
differences between groups were performed with Chi-Square tests,
one-way analyses of variance followed by Tukey’s multiple
comparison tests or t-tests using Graphpad Prism software
(Graphpad Inc, La Jolla, CA, USA). mRNA levels were log-
converted before analysis. Correlations were analysed by Spear-
man’s correlation coefficient. All tests were calculated as two-tailed
and a P-level below 0.05 was considered statistically significant.
Results
Sequence analysis
The INHA sequence was analysed in 37 unique ACC tissues (12
fresh frozen, 25 paraffin-embedded). Results from the sequence
analyses have been summarized in Table 2.
In total, sequencing of the INHA gene in 37 ACCs revealed 10
novel rare genetic variants in 8 ACCs. One ACC harboured three
heterozygous variants (277G.A, –63A.G and –56G.T) in the
59UTR, whereas a heterozygous variant directly after the stop
codon (*1G.A) was detected in another ACC. We localized three
intronic variants, located 179, 72 and 9 bps upstream of the intron
1-exon 2 border. In the coding region of INHA we detected 1
synonymous nucleotide change (75C.T, Ala25Ala) and 2
missense variants, in 3 distinct ACCs. The latter both comprised
heterozygous CRT variants, at bps 215 and 552, leading to serine
to phenylalanine changes at amino acids 72 and 184, respectively.
In our complete series of ACC samples, the –124A.G SNP,
rs11893842, was the most prevalent genetic variation with a minor
allele frequency (MAF) of 24%, compared to 44% in a reference
population (www.1000genomes.org [27]). Furthermore, the minor
allele of the intronic SNP IVS1-87G.A (rs116399602) was
present in 16% of ACC samples, seemingly higher than in healthy
individuals (2.8% MAF). Rs7588807 (IVS1-314G.T) was only
measured in the subset of frozen DNA samples. The minor T
allele was previously reported to occur in 48% in control subjects;
the ACCs showed a lower MAF of 29%. Rs35118453 (216C.T)
and rs12720063 (532C.T) were present at low frequencies,
comparable to reference [27]: 9% and 12%, respectively.
Rs144941390, rs374972575 and rs148455844 within the INHA
gene were each detected in one ACC sample.
Methylation analysis
The first series in which INHA promoter methylation was
investigated, encompassed DNA from 3 normal adrenal glands
and 12 ACCs. For the 4 CpG dinucleotides 558, 599, 719 and
751 bps upstream of the INHA start site low methylation ratios
were obtained in all samples tested: 4.461.1%, 4.560.8%,
1.760.7% and 2.560.6% (mean6SEM), respectively. Further-
more, there were no differences between normal adrenal tissues
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and ACCs (data not shown). The CpGs in proximity to the start
site were methylated to a higher degree in a subset of samples;
therefore we analysed an additional 7 ACCs with the downstream
primer pair only.
Results of the methylation analysis of CpGs at 2285, 2241, 2
203 and2149 are depicted in Figure 2. Five ACCs had aberrantly
high methylation rates of all four proximal CpGs investigated in
the INHA promoter. Average methylation ratio of these ACCs
was 47.763.9%, compared to 18.460.6% for normal adrenals
(P = 0.0052) and 9.861.1% for the other ACCs (P,0.0001). The
difference in methylation between normal adrenals and the other
ACCs was also statistically significant (P = 0.020). The percentage
of INHA promoter methylation in the ACC samples was not
associated with tumor characteristics, such as hormonal overpro-
duction, van Slooten index or ENSAT stage (data not shown).
Expression analysis
INHA mRNA expression levels were measured in normal
adrenal (n = 10), adrenocortical hyperplasia (n = 20), adenoma
(ADA, n= 11) and ACC (n= 25) tissues. The cohort included 10
normal adrenal, 4 adrenal hyperplasia and 14 ACC samples in
which INHA levels were reported before [16]. The present
analysis showed absence of INHA expression in 3 ACC whereas
the other ACCs demonstrated a wide range of expression from
0.080 to 220 arbitrary units (A.U.). Overall, there were no
significant differences between the levels of INHA expression in all
groups investigated (Figure 3A). Also, mRNA levels of INHA in
ACCs were not related to tumor characteristics (data not shown).
Of the 3 ACC samples with rare genetic variants in the INHA
exons, only one was available for expression analysis; this ACC
harbouring the S184F change showed a normal level of INHA
mRNA (15 A.U., Figure 3A, open circle). When stratified for the
five common SNPs, only the rs11893842 gene variation was
associated with changes in INHA mRNA: mean expression in
tissues with the AA genotype was 4.761.9 A.U., compared to
26611 A.U. for the AG/GG genotypes (P = 0.034, Figure 3B).
Combined mRNA and methylation analyses were available for
15 tissues. Overall, there was a significant negative association
between the average methylation ratio of the proximal CpG
islands and INHA mRNA expression (Figure 3C, rs =20.701,
p = 0.0036).
Serum inhibin pro-aC levels were available in a subset of
patients. There were no significant relations between serum
inhibin pro-aC Z-scores on one hand and methylation ratio (n = 9,
rs =20.10, P= 0.81, data not shown) or mRNA expression
(n= 13, rs =20.47, P= 0.10, Figure 3D) on the other. Inhibin
pro-aC levels were only available for one ACC patient with rare
INHA variants: this premenopausal female patient with three rare
variants in the 59UTR of INHA had highly increased inhibin pro-
aC levels at 3000 ng/l (normal,780 ng/l).
Discussion
The inhibin a-subunit has been implicated in adrenocortical
tumorigenesis since it was observed that gonadectomized Inha
2/2 mice developed adrenocortical carcinomas with almost
complete penetrance [11]. Loss of INHA expression has been
detected in only a small subgroup of human ACCs
[16,17,18,20,28,29], pleading against a significant tumor suppres-
sor role of INHA in human adrenocortical carcinogenesis. This is
the first study showing that the large variation in INHA expression
in ACCs is partly caused by methylation and common genetic
Figure 2. INHA methylation analysis in adrenocortical tissues. Quantitative methylation analysis of four CpG dinucleotides in the INHA
promoter was performed in 3 normal adrenals and 19 ACCs. Individual CpGs are indicated on the x-axis by the bp number located 59 from the ATG
start site. 0 indicates no methylation of DNA whereas 1 indicates that all DNA tested in the tissue sample is methylated. Individual data points are
composed of a mean of triplicate measurements.
doi:10.1371/journal.pone.0104944.g002
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variation of the INHA promoter and is not due to rare genetic
variants.
In the murine knockout model, Inha is thought to predispose
subcapsular adrenocortical cells to undergo a phenotypic switch to
gonadal-like cells [11,12,14]. This has been hypothesized to be
caused by increased availability of the TGF-b type III receptor
betaglycan leading to augmented TGF-b2 signalling [13]. The
concomitant rise in circulating gonadotropin levels could ensure
proliferation of adrenocortical cells through a cyclin D2-depen-
dent pathway [30]. Although histology of these tumors resembles
that of adrenocortical carcinoma in man [11] they are functionally
more comparable to estrogen-secreting gonadal-like cells [12].
Whether local knockdown of INHA in human adrenocortical cells
contributes to adrenocortical tumorigenesis is unknown. Since the
occurrence of ACCs shows predominance in postmenopausal
women who have increased gonadotropin levels, this mechanism
could occur in this subgroup of patients.
Previous expression studies have revealed that the inhibin a-
subunit is not expressed in a small subset of ACC samples
[16,17,18,20,28,29]. In contrast, in vivo studies have revealed
increased levels of the inhibin a-subunit in serum of patients with
ACC [21,31,32]. These findings are likely to be a consequence of
the wide variation in tumor INHA expression levels, in the current
study over a 1000-fold. Causes of the loss of or variation in INHA
expression were unknown.
One previous study has investigated INHA genetic variants in
ACCs. Longui et al. [19] studied pediatric ACC patients with
germline TP53 mutations and found 3 rare, heterozygous INHA
variants in 6 out of 46 (13%) patients. Of these three novel
variants, one (G227A, rs12720061) was subsequently shown to be
a common SNP and did not occur in our ACC cohort.
Implications of the other two genetic variants (P43A and
A257T) are unknown; they were not found in the current
investigation of sporadic ACCs. Interestingly, the above men-
tioned study found loss of heterozygosity (LOH) in the vicinity of
the INHA gene in eight out of nine ACCs studied [19], suggesting
that LOH could cause decreased expression levels. Furthermore,
comparative genomic hybridization analyses of human ACCs
described sporadic chromosomal loss of the INHA region at 2q33-
36, with a predominance in childhood tumors [33,34,35]. On the
other hand, the inhibin a-subunit was previously shown to be
overexpressed in pediatric ACCs [21].
In the current study, two novel heterozygous missense genetic
variants were detected. The serine to phenylalanine substitutions
at amino acids 72 and 184 might affect the activity of the resulting
inhibin a-subunit, but since the function of inhibin in the human
adrenal gland is unknown [36], it is difficult to investigate the
consequences of potentially altered activity. The tumor harbouring
the S184F change expressed a normal level of INHA mRNA, but
function or protein degradation could still be affected by the
introduction of the benzyl side ring. The genetic variants located
Figure 3. INHA mRNA analysis in adrenocortical tissues. (A) Quantitative INHA mRNA analysis was comparable in normal adrenals (Nl, n = 10),
adrenocortical hyperplasia (Hyp, n = 20), adenomas (ADA, n = 11) and carcinomas (ACC, n = 25). The ACC sample harbouring the S184F variantis
displayed as an open circle. Bar represents mean. (B) Variation in rs11893842 (2124A.G) was associated with changes in INHA gene expression. Bars
represent means, *P,0.05. (C) Negative association between promoter methylation of the INHA gene and INHA mRNA expression (r =20.701,
P = 0.0036). (D) Lack of correlation between INHA mRNA expression and serum inhibin pro-aC Z-scores in ACC patients (r =20.473, p = 0.10).
doi:10.1371/journal.pone.0104944.g003
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179, 72 and 9 bps upstream of the intron-exon border might lead
to alternative splicing of the INHA gene. Importantly, no
homozygous variants were detected, pleading against total
knockout of INHA leading to ACC formation. Unfortunately,
we had only one patient with INHA variants and concomitantly
available serum inhibin pro-aC levels. Here, high serum levels
were found despite three variants in the promoter region raising
the probability of increased promoter activity. Given the low
frequency of INHA genetic variants in sporadic and familial ACCs
[19], these DNA changes might only be involved in adrenocortical
tumorigenesis in a small subset of ACC patients. Several common
INHA SNPs were detected in our patients. Minor alleles of
rs11893842 and rs758807 were found to occur in ACC patients at
lower frequencies than previously reported in healthy cohorts,
which might suggest that the major alleles of these SNPs play a
role in adrenal oncogenesis. Intriguingly, the minor allele of
rs11893842, located in the promoter region in close proximity to
crucial regulatory sequences [25,26], was associated with lower
levels of INHA mRNA expression. The lower frequency of this
SNP in ACC samples appears to contradict the hypothesis that
INHA is a tumor suppressor in human ACC.
Methylation of promoter regions of tumor suppressor genes is a
common mechanism involved in carcinogenesis [23]. Decreased
INHA expression in ACCs could be caused by increased
methylation of the INHA promoter. Methylation of follistatin,
involved in the activin and inhibin signalling pathway as an activin
antagonist, was previously found in the human ACC cell line
H295R [37]. We now show that a subset of human ACCs (21%)
has an increased methylation ratio of several CpGs in the INHA
promoter, in contrast to the majority of ACCs that show a
decreased methylation of the INHA promoter compared to
normal adrenal tissue. This wide range of methylation presumably
accounts for part of the wide INHA expression range, as shown by
the inverse relationship between INHA promoter methylation and
INHA mRNA expression. This epigenetic modification in the
INHA promoter and rs11893842 might also be involved in
regulatory control of INHA expression in the other INHA-
expressing tissues, i.e. gonads and placenta.
The levels of methylation of the INHA promoter and INHA
mRNA expression were not associated with serum inhibin pro-aC
levels. Furthermore, we previously found no association between
pro-aC levels and tumor stage or size [21]. Therefore, these levels
could be primarily dependent on (post-) translational modifica-
tions, tumor cell activity, or clearance from the circulation.
Study limitations include the small sample size, uncertainty
about the presence of LOH and whether the novel variants are
germ line or somatic. Given the very low incidence of INHA
genetic variants in this substantial set of 37 ACCs, it is very
unlikely that INHA mutations play a significant role in ACC
formation in man. Although LOH was not studied directly in these
samples, the occurrence of heterozygous variants in the ACCs
pleads against complete knockout of the gene. Importantly, only
homozygous Inha knock-out mice developed adrenocortical
tumors [11] pleading against tumorigenic potential of single copy
number deletion. Finally, paired sequencing of normal and tumor
tissue might reveal whether the previously undescribed variants
have a germ line or somatic origin, but this was not available for
the current study. These findings reveal a novel link between
methylation and expression of inhibin. Knockdown of the inhibin
a-subunit during ACC formation through methylation might
predispose to unopposed paracrine TGF-b or activin action on
adrenocortical proliferation or steroidogenesis. Restoring inhibin
and also follistatin [37] levels in ACC by demethylating agents
might contribute to the antiproliferative and steroidogenic effects
seen with DNA methylation inhibitor 5-aza-29-deoxycytidine in
adrenocortical cells [38]. Conversely, methylation of the inhibin
promoter might also be a common regulatory mechanism of
inhibin expression in gonadal, adrenal and placental tissue and
treatment with demethylating agents could be speculated to affect
inhibin production in these organs.
In conclusion, aberrant methylation and common genetic
variation within the promoter region of the INHA gene are
associated with INHA mRNA expression in human ACC. These
genetic and epigenetic INHA changes could contribute to human
adrenocortical tumorigenesis, similar to the situation in the murine
Inha knockout model. Rare INHA variants do not appear to be
involved in the pathophysiology of sporadic ACC.
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